Bobby is currently Life Science Partner at IP Group plc. He joined Touchstone Innovations (now IP Group) in 2015 from Novo Seeds, the early stage investment arm of Novo AS where he worked as Investment Director. Bobby has 18 years’ experience in the Life Science industry covering drug development, business development and venture capital investment. In addition to Autifony he is a Non-Executive Director of Storm Therapeutics, Artios Pharma, Pulmocide, Enterprise Therapeutics, Oxular, and Mission Therapeutics.
Bobby holds a PhD in Biology from the University of Virginia and an undergraduate degree in Biochemistry from the University of Rochester.